FOSUN PHARMA(600196.SH)

event-tracking

May14

Fosun Pharma: Expected to submit NDA by year-end

13:36

May13

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

10:37

Fosun Pharma Industry Acquires Exclusive Option from AriBio

10:34

May10

Fosun Pharma Subsidiary Approved for Phase I Clinical Trial of HLX05-N for Metastatic Colorectal Cancer in the US

07:50

May8

Fosun Pharmaceutical's Subsidiary's Venlafaxine Hydrochloride Extended-Release Tablets Approved for Registration

08:30

April30

Fosun Pharma subsidiary obtains approval for Sodium Nitroprusside Injection registration

08:29

schedules

filings

April28

Earning Release(CST)

FY2026 Q1 Earning Release (CNY) Revenue 10.07 B, Net Income 870.83 M, EPS 0.33

March24

Earning Release(CST)

FY2025 Q4 Earning Release (CNY) Revenue 12.27 B, Net Income 847.27 M, EPS 0.32

October28

Earning Release(CST)

FY2025 Q3 Earning Release (CNY) Revenue 9.879 B, Net Income 821.33 M, EPS 0.3099

view-more

topGainers

topLosers

cn_connect

table_symbol

table_price

table_%change

table_change

view-more